Mounjaro Dosage Chart: Dose Steps and Missed-Dose Rules

Mounjaro dosing is a prescriber-led decision. The chart below explains the current US label; it is not a calendar telling every reader to increase their dose. Your prescription, treatment response and tolerability determine the plan.

Mounjaro dosage chart: strengths and escalation

The August 2026 US prescribing information lists a 2.5 mg weekly starting dose and increases of 2.5 mg only if additional glycemic control is needed, after at least four weeks at the current dose. Source: prescribing information, section 2.1.

Weekly strength	How to read the dose step
2.5 mg	Labeled starting dose
5 mg	Next strength when escalation is prescribed
7.5 mg	Next 2.5 mg increment
10 mg	Next increment; pediatric maximum
12.5 mg	Adult dose step only
15 mg	Adult maximum

The pediatric limit applies to patients aged 10 years and older; this table is not a pediatric treatment plan. Reaching the largest number is not the objective. A box labeled 7.5 mg is not an instruction to progress automatically to 10 mg on a particular date.

A practical way to use this chart: compare the strength on your current prescription with your written plan. If they differ, ask the dispensing pharmacist or prescriber to reconcile them before using the medicine. Do not calculate a replacement dose from leftover liquid or from another person's pen.

Missed-dose rules

The label specifies a 96-hour window after a missed dose. Within that window, the missed dose can be taken; beyond it, the dose is skipped. A change of weekly injection day requires at least 72 hours between doses. These rules do not establish a restart dose after a longer treatment interruption. Prescribing information, section 2.1.

For an interruption involving several missed injections, illness or loss of access, contact the prescriber. Bring the date and strength of the last injection rather than guessing from a standard chart. Our guide to weight regain after stopping GLP-1 treatment explains why a longer-term follow-up plan also matters.

Mounjaro and Zepbound are different prescriptions

Both contain tirzepatide, but their labeled uses and dosing instructions must be checked separately. Mounjaro's US label covers type 2 diabetes and specified cardiovascular-risk reduction; Zepbound has its own indications and maintenance-dose recommendations. Do not transfer a Zepbound maintenance-dose list into a Mounjaro plan. Mounjaro label; Zepbound label.

For the distinction between trial results and personal treatment choice, see tirzepatide versus semaglutide: reading the evidence. Research comparisons cannot select an individual's dose.

Check the presentation before using a dose

Mounjaro is supplied in more than one presentation, including single-dose products and multidose products. Device instructions are specific to the product dispensed. Ask for a demonstration when the presentation changes; a video for a different pen can be misleading. Manufacturer's administration guidance.

Keep these three pieces of information together:

• The name and strength on the prescription.
• The exact pen or vial presentation on the carton.
• The written dosing and storage instructions supplied with that presentation.

See our storage table by medication and device before applying a room-temperature limit. There is no single storage window for every Mounjaro device.

Symptoms and circumstances to raise promptly

The manufacturer advises urgent contact for persistent severe abdominal pain, severe or persistent stomach symptoms, and possible gallbladder symptoms. Serious allergic symptoms need immediate medical help. Insulin and sulfonylureas can increase the risk of low blood sugar when used with Mounjaro. Safety information.

Tell the care team about pregnancy plans, breastfeeding, oral contraception and upcoming anesthesia. The label advises additional or non-oral contraception for four weeks after starting and after each dose increase. An individualized plan is needed; an internet chart cannot resolve these situations. Manufacturer's safety guidance.

For background, read our explainers on gastroparesis and GLP-1 medications, gallbladder risk and warning symptoms, pregnancy considerations and procedures involving anesthesia. These support a clinical conversation, not self-directed dose changes.

Questions for your next appointment

1. What is my current prescribed strength, and what would justify changing it?
2. What should I do if side effects prevent eating or drinking normally?
3. Who should I contact about a missed dose or interruption?
4. Is the device in this refill the same as the one I was trained to use?
5. When will we reassess benefit, tolerability and the treatment plan?

Sources and revision

Sources were checked September 15, 2026: US Mounjaro prescribing information, US Zepbound prescribing information, and Lilly's use and safety guidance.

This revision replaces the previous automatic week-by-week escalation framing, unsupported maintenance-dose restrictions and universal device instructions. Prepared by the editorial team with AI assistance; no independent physician review is claimed.